410 related articles for article (PubMed ID: 33162546)
21. Immunogenic neoantigens derived from gene fusions stimulate T cell responses.
Yang W; Lee KW; Srivastava RM; Kuo F; Krishna C; Chowell D; Makarov V; Hoen D; Dalin MG; Wexler L; Ghossein R; Katabi N; Nadeem Z; Cohen MA; Tian SK; Robine N; Arora K; Geiger H; Agius P; Bouvier N; Huberman K; Vanness K; Havel JJ; Sims JS; Samstein RM; Mandal R; Tepe J; Ganly I; Ho AL; Riaz N; Wong RJ; Shukla N; Chan TA; Morris LGT
Nat Med; 2019 May; 25(5):767-775. PubMed ID: 31011208
[TBL] [Abstract][Full Text] [Related]
22. Neoantigens in cancer immunotherapy.
Schumacher TN; Schreiber RD
Science; 2015 Apr; 348(6230):69-74. PubMed ID: 25838375
[TBL] [Abstract][Full Text] [Related]
23. Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens.
Kiyotani K; Chan HT; Nakamura Y
Cancer Sci; 2018 Mar; 109(3):542-549. PubMed ID: 29288513
[TBL] [Abstract][Full Text] [Related]
24. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis.
Turajlic S; Litchfield K; Xu H; Rosenthal R; McGranahan N; Reading JL; Wong YNS; Rowan A; Kanu N; Al Bakir M; Chambers T; Salgado R; Savas P; Loi S; Birkbak NJ; Sansregret L; Gore M; Larkin J; Quezada SA; Swanton C
Lancet Oncol; 2017 Aug; 18(8):1009-1021. PubMed ID: 28694034
[TBL] [Abstract][Full Text] [Related]
25. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.
van den Bulk J; Verdegaal EME; Ruano D; Ijsselsteijn ME; Visser M; van der Breggen R; Duhen T; van der Ploeg M; de Vries NL; Oosting J; Peeters KCMJ; Weinberg AD; Farina-Sarasqueta A; van der Burg SH; de Miranda NFCC
Genome Med; 2019 Dec; 11(1):87. PubMed ID: 31888734
[TBL] [Abstract][Full Text] [Related]
26. MHC class II restricted neoantigen: A promising target in tumor immunotherapy.
Sun Z; Chen F; Meng F; Wei J; Liu B
Cancer Lett; 2017 Apr; 392():17-25. PubMed ID: 28104443
[TBL] [Abstract][Full Text] [Related]
27. Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy.
Zhang X; Qi Y; Zhang Q; Liu W
Biomed Pharmacother; 2019 Dec; 120():109542. PubMed ID: 31629254
[TBL] [Abstract][Full Text] [Related]
28. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
29. New emerging targets in cancer immunotherapy: the role of neoantigens.
De Mattos-Arruda L; Blanco-Heredia J; Aguilar-Gurrieri C; Carrillo J; Blanco J
ESMO Open; 2020 Apr; 4(Suppl 3):e000684. PubMed ID: 32269031
[TBL] [Abstract][Full Text] [Related]
30. A Comprehensive Survey of Genomic Alterations in Gastric Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets.
Chen C; Zhou Q; Wu R; Li B; Chen Q; Zhang X; Shi C
Biomed Res Int; 2019; 2019():2183510. PubMed ID: 31781598
[TBL] [Abstract][Full Text] [Related]
31. Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy.
Okada M; Shimizu K; Fujii SI
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269735
[TBL] [Abstract][Full Text] [Related]
32. Neoantigens and NK Cells: "Trick or Treat" the Cancers?
Lv D; Khawar MB; Liang Z; Gao Y; Sun H
Front Immunol; 2022; 13():931862. PubMed ID: 35874694
[TBL] [Abstract][Full Text] [Related]
33. Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy.
Li G; Mahajan S; Ma S; Jeffery ED; Zhang X; Bhattacharjee A; Venkatasubramanian M; Weirauch MT; Miraldi ER; Grimes HL; Sheynkman GM; Tilburgs T; Salomonis N
Sci Transl Med; 2024 Jan; 16(730):eade2886. PubMed ID: 38232136
[TBL] [Abstract][Full Text] [Related]
34. ProGeo-neo: a customized proteogenomic workflow for neoantigen prediction and selection.
Li Y; Wang G; Tan X; Ouyang J; Zhang M; Song X; Liu Q; Leng Q; Chen L; Xie L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):52. PubMed ID: 32241270
[TBL] [Abstract][Full Text] [Related]
35. T Cell Recognition of Tumor Neoantigens and Insights Into T Cell Immunotherapy.
Sim MJW; Sun PD
Front Immunol; 2022; 13():833017. PubMed ID: 35222422
[TBL] [Abstract][Full Text] [Related]
36. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
37. Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy.
Blaeschke F; Paul MC; Schuhmann MU; Rabsteyn A; Schroeder C; Casadei N; Matthes J; Mohr C; Lotfi R; Wagner B; Kaeuferle T; Feucht J; Willier S; Handgretinger R; StevanoviĆ S; Lang P; Feuchtinger T
Cytotherapy; 2019 Sep; 21(9):973-986. PubMed ID: 31351799
[TBL] [Abstract][Full Text] [Related]
38. Neoantigens Derived from Recurrently Mutated Genes as Potential Immunotherapy Targets for Gastric Cancer.
Zhou J; Zhao W; Wu J; Lu J; Ding Y; Wu S; Wang H; Ding D; Mo F; Zhou Z; Teng L; Chen S
Biomed Res Int; 2019; 2019():8103142. PubMed ID: 31312661
[TBL] [Abstract][Full Text] [Related]
39. Mutation-Derived Neoantigens for Cancer Immunotherapy.
Castle JC; Uduman M; Pabla S; Stein RB; Buell JS
Front Immunol; 2019; 10():1856. PubMed ID: 31440245
[TBL] [Abstract][Full Text] [Related]
40. Developing neoantigen-targeted T cell-based treatments for solid tumors.
Yamamoto TN; Kishton RJ; Restifo NP
Nat Med; 2019 Oct; 25(10):1488-1499. PubMed ID: 31591590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]